Eli Lilly (LLY)

Good news for Hims & Hers stock spooks Lilly and Novo investors.

FDA to increase surprise inspections at foreign facilities as U.S. companies pour billions into domestic drug and device manufacturing.

Eli Lilly and Company (NYSE: LLY) shares are trading lower Tuesday. The stock appears to be moving in reaction to an executive order from the Trump administration aimed at boosting domestic drug manufacturing.

President Donald Trump signed an executive order Monday directing the FDA to accelerate approvals for domestic pharmaceutical manufacturing facilities as his administration prepares to announce new tariffs on imported medicines within two weeks

"Too big to fail" is how we would describe the megacap stocks in this article today. While they will likely stand the test of time, it’s not all sunshine and rainbows as their scale can limit their ability to find new sources of growth.

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

Eli Lilly's Zepbound loses CVS coverage to Wegovy, prompting analyst debate on pricing pressures and long-term obesity market potential.

GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock investors.

U.S. stock futures are in the green early Friday, after another winning day for the markets in the regular session on Thursday.

Viking's leading drug candidate could be a blockbuster in the weight loss market, which experts believe could grow to $150 billion over the coming years.

Wall Street Rebounds as Microsoft and Meta Impress, Eyes Turn to Jobs Report and Tariff Tensions

Let's have a look at the top S&P500 gainers and losers one hour before the close of the markets of today's session.

Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 11% in the afternoon session after the company reported weak first quarter 2025 results which included an EPS miss due to lower-than-expected profitability and full-year EPS guidance that missed significantly. On the other hand, Eli Lilly narrowly topped analysts' revenue expectations, fueled by surging demand for Mounjaro and Zepbound, which together drove a 45% year-over-year increase in total sales. Still, this was a softer quarter.

Let's have a look at what is happening on the US markets on Thursday. Below you can find the S&P500 stocks with an unusual volume in today's session.

Stay updated with the movements of the S&P500 index in the middle of the day on Thursday. Discover which stocks are leading as top gainers and losers in today's session.

Wall Street pushed higher in midday trading, with the S&P 500 on track for its eighth consecutive gain — its longest winning streak since November 2023. The index rose about 1% to 5,560, fully recovering the losses sustained after former President Donald Trump announced trade tariffs on April 2.